P395 Management of pouch vaginal fistulae in ulcerative colitis: A 35-year experience
ECCO'20 Vienna
2020
P397 Surveillance in ulcerative colitis: Can we predict the risk for intraepithelial neoplasia?
ECCO'20 Vienna
2020
P398 The early appearance of anti-drug antibodies during the induction phase predicts the clinical response of adalimumab and infliximab in IBD
ECCO'20 Vienna
2020
P399 Endoscopic and histologic outcome in tofacitinib treated refractory moderate-to-severe ulcerative colitis: A prospective real-life cohort
ECCO'20 Vienna
2020
P400 Understanding the impact of TNF-α antagonists on the severity of non-melanoma skin cancer in inflammatory bowel disease and the consequences for therapy
ECCO'20 Vienna
2020
P401 Sarcopenia in children and young adults with primary sclerosing cholangitis and IBD
ECCO'20 Vienna
2020
P402 Prediction of emergency department re-visit among Crohn’s disease patients: a retrospective study
ECCO'20 Vienna
2020
P403 Post hoc examination of VISIBLE 1 data for baseline predictors of response to 2 or 3 IV doses of vedolizumab for adults with moderate-to-severe ulcerative colitis
ECCO'20 Vienna
2020
P404 Prolonged steroid exposure prior to admission is associated with increased likelihood of rescue therapy and colectomy in acute severe ulcerative colitis
ECCO'20 Vienna
2020
P405 Comparison of long-term outcomes of infliximab vs. adalimumab in 1488 biologic-naive Korean patients with Crohn’s disease
ECCO'20 Vienna
2020
P406 Adherence, acceptability and serum trough concentration of adalimumab autoinjector in quiescent patients with inflammatory bowel diseases
ECCO'20 Vienna
2020
P407 Is the rapid infliximab infusion a safe and cost-saving strategy in paediatric inflammatory bowel disease?
ECCO'20 Vienna
2020
P408 Long-term impact of the decrease of infliximab trough levels on the disease course in Inflammatory Bowel Disease patients under maintenance treatment with infliximab
ECCO'20 Vienna
2020
P409 Endoscopic and histological activity is associated with non-response to biologic therapy in ulcerative colitis
ECCO'20 Vienna
2020
P410 Could the disease become ‘a friend’? The mediating role of illness acceptance on self-efficacy and quality of life of gastroenterological patients
ECCO'20 Vienna
2020
P412 Maintenance therapy of vedolizumab (VDZ) after induction of remission by tacrolimus (TAC) in patients with refractory ulcerative colitis (UC)
ECCO'20 Vienna
2020